Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCND2 | P30279 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449361 | 0.85 | IGF1R (0.61) | SYKKDRGRM5IGF1RCDK1 | |
| SCHEMBL3447328 | 0.83 | NFKB1 (0.57) | SYKGRM5IGF1RCDK1 | |
| SCHEMBL3345413 | 0.83 | SYK (0.57) | SYKKDRGRM5TBK1PDPK1 | |
| SCHEMBL3125757 | 0.82 | IGF1R (0.68) | SYKKDRPDPK1IGF1RNTRK1 | |
| SCHEMBL3344858 | 0.80 | MAPK1 (0.57) | SYKKDRIGF1R | |
| SCHEMBL3344041 | 0.80 | ULK1 (0.57) | SYKKDRGRM5TBK1PDPK1 | |
| SCHEMBL3449597 | 0.79 | HDAC3 (0.53) | SYKKDRIGF1RCDK1 | |
| SCHEMBL180866 | 0.79 | KDR (0.54) | SYKKDRGRM5CDK4CCND1 | |
| SCHEMBL3449948 | 0.78 | CDK19 (0.50) | SYKIGF1R | |
| SCHEMBL1935615 | 0.76 | SYK (0.43) | SYKKDRGRM5TBK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | SYK 804/4885KDR 4837/4885GRM5 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.